Table of Content

1. Japan Cancer Drug Market Insight
1.1 Overview
1.2 Current Market Scenario


2. Japan - Cancer Prevalence & Statistics
2.1 Overview
2.2 By Cancer Type
2.2.1 Colorectum Cancer
2.2.2 Lung Cancer
2.2.3 Stomach Cancer
2.2.4 Prostate Cancer
2.2.5 Breast Cancer
2.3 By Gender & Age


3. Japan - Drug Approval & Regulation Landscape
3.1 Japan - Drug Regulatory Agencies
3.1.1 Ministry of Health, Labor & Welfare (MHLW)
3.1.2 Pharmaceuticals and Medical Devices Agency (PMDA)
3.2 Drug Approval Process
3.2.1 New Drug Approval (NDA) Application Process
3.2.2 Generic Drug approval Process
3.2.3 Orphan Drug Approval


4. Japan - Drug Pricing & Reimbursement Policies
4.1 Drug Pricing in Japan
4.1.1 Pricing of New Pharmaceuticals
4.1.2 Pricing of Generics & Biosimilars
4.2 Reimbursement Policies



5. Japan Cancer Drug Market - Clinical Insight
5.1 By Phase
5.2 By Status
5.3 By Cancer Type
5.3.1 Breast Cancer
5.3.2 Colorectal Cancer
5.3.3 Prostate Cancer
5.3.4 Lung Cancer
5.3.5 Stomach Cancer


6. Japan Breast Cancer Drug Market - Availability, Dosage & Price Analysis
6.1 HER2 inhibitors
6.1.1 Herceptin
6.1.2 Kadcyla
6.1.3 Perjeta (Pertuzumab)
6.1.4 Enhertu (Antibody Drug Conjugate)
6.1.5 Tykerb (Lapatinib)
6.2 Hormone Therapy
6.2.1 Letrozole
6.2.2 Anastrazole (Arimidex)
6.2.3 Megestrol
6.2.4 Faslodax (Fulvestrant)
6.2.5 Toremifene
6.2.6 Exemestane (Aromasin)
6.3 CDK 4/6 Inhibitors
6.3.1 Verzenio (Abemaciclib)
6.3.2 Ibrance



7. Japan Prostate Cancer Drug Market – Availability, Dosage & Price Analysis
7.1 Patented Drugs
7.1.1 Xtandi (Enzalutamide)
7.1.2 Erleada (Apalutamide)
7.1.3 Nubeqa
7.1.4 Xofigo (Radium Ra 223 dichloride)
7.2 Generic Drugs
7.2.1 Abiraterone
7.2.2 Bicalutamide
7.2.3 Nilutamide
7.2.4 Flutamide


8. Japan Lung Cancer Drug Market – Availability, Dosage & Price Analysis
8.1 Patented Drugs
8.1.1 Alimta (Pemetrexed)
8.1.2 Alecensa (Alectinib)
8.1.3 Gilotrif
8.1.4 Lorbrena
8.1.5 Portrazza (Necitimumab)
8.1.6 Rozlytrek
8.1.7 Tagrisso
8.1.8 Vizimpro (Dacomitinib)
8.1.9 Xalkori (Crizotinib)
8.1.10 Zykadia (Certinib)
8.2 Generic Drugs
8.2.1 Vinorelbine



9. Japan Colorectum Cancer Drug Market – Availability, Dosage & Price Analysis
9.1 Patented drugs
9.1.1 Lonsurf
9.1.2 Vectibix (Panitumumab)
9.1.3 Zaltrap
9.2 Generic Drugs
9.2.1 Irinotecan
9.2.2 Oxaliplatin


10. Other Leading Cancer Drugs – Availability, Dosage, Price & Sales Analysis

10.1 Avastin (Bevacizumab)
10.2 Mabthera/Rituxan
10.3 Tecentriq
10.4 Opdivo
10.5 Revlimid
10.6 Keytruda
10.7 Imbruvica


11. Japan Cancer Biosimilar Market – Availability, Dosage & Price Analysis
11.1 Biosimilar of Avastin
11.2 Biosimilars of Herceptin
11.3 Rituxan’s Biosimilar


12. Japan Cancer Drugs Market Dynamics
12.1 Market Drivers
12.2 Challenges to Overcome



13. Japan Cancer Drug Market Future Outlook


14. Japan Cancer Clinical Pipeline By Company, Indication & Phase
14.1 Research
14.2 Preclinical
14.3 Clinical
14.4 Phase-I
14.5 Phase-I/II
14.6 Phase-II
14.7 Phase-II/III
14.8 Phase-III
14.9 Preregistration
14.10 Registered


15. Japan Marketed Cancer Drug Clinical Insight by Companies & Indication


16. Competitive Landscape
16.1 Regional Companies
16.1.1 Takeda Pharmaceuticals
16.1.2 Daiichi Sankyo
16.1.3 Kyowa Kirin
16.1.4 Mitsubishi Taneba Pharma Co.
16.1.5 Otsuka Pharmaceutical Co. Ltd.
16.1.6 Eisai Co. Ltd.
16.1.7 Astellas Pharma
16.2 Multinational Company
16.2.1 Novartis
16.2.2 Amgen
16.2.3 Eli Lilly
16.2.4 Merck
16.2.5 Pfizer
16.2.6 GlaxoSmithKline plc
16.2.7 Roche